Encomium for Karen Rothenberg

Ellen Wright Clayton

Follow this and additional works at: https://digitalcommons.law.umaryland.edu/jhclp

Recommended Citation
Available at: https://digitalcommons.law.umaryland.edu/jhclp/vol22/iss2/4

This Tribute is brought to you for free and open access by the Academic Journals at DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of Health Care Law and Policy by an authorized editor of DigitalCommons@UM Carey Law. For more information, please contact smccarty@law.umaryland.edu.
ENCOMIUM FOR KAREN ROTHENBERG

ELLEN WRIGHT CLAYTON, MD, JD*

Karen Rothenberg is an extraordinary scholar and leader who changed the course of my career. In law school, I wrote my note for journal on reproductive genetic testing, which appeared in 1978. Then I went to medical school and did a residency in pediatrics. As a young assistant professor, I had given a few talks about genetics and law but was still trying to find my way as an investigator and scholar.

That all changed when Karen and Elizabeth Thomson invited me to give a talk on legal and regulatory issues at an NIH conference on Reproductive Genetic Testing: Its Impact on Women in November, 1991. The conferees consisted of an all-star cast of leading women scholars from a variety of areas including philosophy, history, disability rights, sociology, anthropology, psychology, law, and obstetrics.¹ The conference was both exhilarating and exhausting because it made clear the excitement, the challenge, and the necessity of working across disciplines to understand issues in their full complexity in order to work toward solutions; lessons that have shaped my own work ever since.

This conference also epitomized the essential characteristics of Karen’s scholarship – her passion for addressing women’s issues, her commitment to understanding from many perspectives what is really at stake, and her insistence on wrestling issues to the ground – no superficial work allowed. I turn first to an example from her work on genetics, our point of first contact. When Jeff Struwing at the National Institutes of Health demonstrated that Ashkenazi Jews had a higher prevalence of specific variants in BRCA1 and BRCA2 that created an intermediate risk of cancer,² Karen went to work. She worried the results of Struwing’s research would stigmatize a recognized and at times disfavored group.³ Her analysis informed later discussions of how to prevent group harm, a

© 2019 Ellen Wright Clayton, MD, JD.

¹Craig-Weaver Professor of Pediatrics, Professor of Law, Professor of Health Policy, Center for Biomedical Ethics and Society, Vanderbilt University.


³K. H. Rothenberg, Breast Cancer, the Genetic “Quick Fix,” and the Jewish community, Ethical, Legal, and Social Challenges, 7 HEALTH MATRIX CLEVEL. 97 (1997); K. H. Rothenberg & A. B. Rutkin,
gnarly and still unresolved dilemma. Noting that individuals from whom the tissue samples had been obtained had not given consent for the use of these specimens, Karen helped to coordinate a survey of Jews about their views about the use of stored tissue for this type of research. This survey also covered their views on the acceptability of using different sources of tissues and about whether consent should be required. The investigators found that while the respondents were generally highly supportive of research, they wanted to provide written consent, particularly if the samples were collected in a clinical rather than a research setting.

Karen is also a zealous advocate in the very best sense of the word. After Struewing’s article appeared, she wrote an editorial that appeared in multiple newspapers arguing that women with these variants should not lose their insurance. She became deeply involved in the National Action Plan for Breast Cancer, a powerful grass roots organization. Additionally, she became involved at the National Institutes of Health and addressed, often in leadership roles, such issues to develop strategies to prevent genetic discrimination for individuals with variants that increased the risk of developing cancer, to create tools to obtain meaningful informed consent for research, and to govern the use of biological specimens. Her work laid the foundation for the passage of the Genetic Information Nondiscrimination Act as well as the ongoing debate about use of biological specimens for research, most recently instantiated in the changes to the Regulations for the Protection of Human Research Participants that are currently going into effect.

Karen’s concern for women was not limited to genetics. Early in her career, she was a vigorous advocate for including women in clinical research, during a time when this surprisingly was a topic of debate. Previously, researchers had

---

usually studied only men because women’s hormonal cycles and potential to become pregnant presented too many complications. Her advocacy carried the day, and although progress has been made, parity has not yet been achieved, particularly for pregnant or “potentially pregnable” women. Karen was also deeply concerned about the HIV/AIDS epidemic, focusing both on the obligations of health care providers and also the impact of this disease on women, pointing out their greatly increased risk of domestic violence.

This discussion represents only part of her scholarly and policy impact. Over the course of Karen’s career, she has written and spoken extensively about the right to die, medical decision-making for children, research ethics, and access to health care. For the last several years, she has explored in great depth the potential value of using drama to reveal new perspectives on the complexities of advances in genomics, ultimately publishing her book, *The Drama of DNA: Narrative Genomics*, with Lynn Wein Bush. Illustrating the power and wisdom of this endeavor, Jules Odendahl-James, an artist-scholar wrote in his book review “Rothenberg and Bush’s narrative . . . scenarios move across time, across professional and personal networks, from the research study to the clinical trial to the medical case. . . . [demonstrating that e]thical and empathetic considerations are not a barrier to cutting-edge research; they are actually key elements to superior, successful medical science.”

What makes Professor Rothenberg’s accomplishments all the more remarkable is that she achieved them while creating a leading health law program from scratch at the University of Maryland, then stepping in as dean of the school, and ultimately advising the leadership of the National Human Genome


Research Institute for many years, all while doing an almost immeasurable amount of service. And to top it off, she was, and is, an unstintingly generous friend and mentor, for which I am supremely grateful.